1210 related articles for article (PubMed ID: 18722046)
21. Updated results of bladder-sparing trimodality approach for invasive bladder cancer.
Zapatero A; Martin de Vidales C; Arellano R; Bocardo G; Pérez M; Ríos P
Urol Oncol; 2010; 28(4):368-74. PubMed ID: 19362865
[TBL] [Abstract][Full Text] [Related]
22. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer.
Freiha F; Reese J; Torti FM
J Urol; 1996 Feb; 155(2):495-9; discussion 499-500. PubMed ID: 8558644
[TBL] [Abstract][Full Text] [Related]
23. The significance of lymphovascular invasion in transurethral resection of bladder tumour and cystectomy specimens on the survival of patients with urothelial bladder cancer.
Streeper NM; Simons CM; Konety BR; Muirhead DM; Williams RD; O'Donnell MA; Joudi FN
BJU Int; 2009 Feb; 103(4):475-9. PubMed ID: 18990174
[TBL] [Abstract][Full Text] [Related]
24. [Bladder preservation or initial cystectomy in T1G3 bladder cancer: which parameters help in therapeutic decision-making?].
Denzinger S; Burger M; Fritsche HM; Ganzer R; Blana A; Wieland WF; Otto W
Aktuelle Urol; 2008 Jan; 39(1):58-61; discussion 62-3. PubMed ID: 18228189
[TBL] [Abstract][Full Text] [Related]
25. External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.
van Onna IE; Oddens JR; Kok ET; van Moorselaar RJ; Bosch JL; Battermann JJ
Eur Urol; 2009 Jul; 56(1):113-21. PubMed ID: 18722048
[TBL] [Abstract][Full Text] [Related]
26. Organ-sparing treatment in muscle-invasive bladder cancer.
Dunst J; Diestelhorst A; Kühn R; Müller AC; Scholz HJ; Fornara P
Strahlenther Onkol; 2005 Oct; 181(10):632-7. PubMed ID: 16220401
[TBL] [Abstract][Full Text] [Related]
27. Selective bladder preservation by combination treatment of invasive bladder cancer.
Kaufman DS; Shipley WU; Griffin PP; Heney NM; Althausen AF; Efird JT
N Engl J Med; 1993 Nov; 329(19):1377-82. PubMed ID: 8413433
[TBL] [Abstract][Full Text] [Related]
28. Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2008 Jul; 54(1):126-32. PubMed ID: 18248875
[TBL] [Abstract][Full Text] [Related]
29. Predictive factors for outcome in invasive bladder cancer treated with alternating chemoradiotherapy.
Sanguineti G; Orsatti M; Sormani MP; Canobbio L; Curotto A; Tognoni P; Giudici S; Franzone P; Boccardo F; Vitale V
Cancer J Sci Am; 1997; 3(4):213-23. PubMed ID: 9263627
[TBL] [Abstract][Full Text] [Related]
30. [Radical cystectomy in patients with non-muscle invasive bladder cancer who fail BCG therapy].
Huguet J; Gaya JM; Sabaté S; Palou J; Villavicencio H
Actas Urol Esp; 2010 Jan; 34(1):63-70. PubMed ID: 20223134
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow up of patients with invasive bladder carcinoma receiving combined cisplatin-based intra-arterial chemotherapy and radiotherapy.
Mori K; Nomata K; Noguchi M; Eguchi J; Hayashi N; Kanetake H
Int J Urol; 2007 Jul; 14(7):591-4. PubMed ID: 17645599
[TBL] [Abstract][Full Text] [Related]
32. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer.
Qureshi KN; Griffiths TR; Robinson MC; Marsh C; Roberts JT; Hall RR; Lunec J; Neal DE
Clin Cancer Res; 1999 Nov; 5(11):3500-7. PubMed ID: 10589764
[TBL] [Abstract][Full Text] [Related]
33. Role of immediate radical cystectomy in the treatment of patients with residual T1 bladder cancer on restaging transurethral resection.
Sternberg IA; Keren Paz GE; Chen LY; Herr HW; Dalbagni G
BJU Int; 2013 Jul; 112(1):54-9. PubMed ID: 23146082
[TBL] [Abstract][Full Text] [Related]
34. An organ-sparing treatment using combined intra-arterial chemotherapy and radiotherapy for muscle-invading bladder carcinoma.
Tsukamoto S; Ishikawa S; Tsutsumi M; Nakajima K; Sugahara S
Scand J Urol Nephrol; 2002; 36(5):339-43. PubMed ID: 12487737
[TBL] [Abstract][Full Text] [Related]
35. Combined modality treatment with bladder preservation for muscle invasive bladder cancer.
Sabaa MA; El-Gamal OM; Abo-Elenen M; Khanam A
Urol Oncol; 2010; 28(1):14-20. PubMed ID: 18818110
[TBL] [Abstract][Full Text] [Related]
36. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy.
Kaufman DS; Winter KA; Shipley WU; Heney NM; Wallace HJ; Toonkel LM; Zietman AL; Tanguay S; Sandler HM
Urology; 2009 Apr; 73(4):833-7. PubMed ID: 19100600
[TBL] [Abstract][Full Text] [Related]
37. Bladder-sparing therapy for muscle-infiltrating bladder cancer.
Pansadoro V; Emiliozzi P
Nat Clin Pract Urol; 2008 Jul; 5(7):368-75. PubMed ID: 18560383
[TBL] [Abstract][Full Text] [Related]
38. [Intraarterial chemotherapy for patients with invasive bladder cancer--clinical effects and preliminary results in bladder preservation].
Uekado Y; Hirano A; Inagaki T; Hiroi A
Gan To Kagaku Ryoho; 1994 Sep; 21(13):2307-10. PubMed ID: 7944466
[TBL] [Abstract][Full Text] [Related]
39. [Bladder preservation for locally advanced bladder cancer by transurethral resection, systemic chemotherapy and radiation].
Honda M; Satoh M; Tujimoto Y; Takada T; Matsumiya K; Fujioka H
Hinyokika Kiyo; 2006 May; 52(5):331-5. PubMed ID: 16758720
[TBL] [Abstract][Full Text] [Related]
40. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy.
Zapatero A; Martin De Vidales C; Arellano R; Ibañez Y; Bocardo G; Perez M; Rabadan M; García Vicente F; Cruz Conde JA; Olivier C
Urology; 2012 Nov; 80(5):1056-62. PubMed ID: 22999456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
